|
ES2590912T3
(es)
|
1997-12-08 |
2016-11-24 |
Merck Patent Gmbh |
Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario
|
|
WO2000058456A2
(en)
*
|
1999-03-30 |
2000-10-05 |
Board Of Regents, The University Of Texas System |
Compositions and methods for modifying toxic effects of proteinacious compounds
|
|
US7067110B1
(en)
|
1999-07-21 |
2006-06-27 |
Emd Lexigen Research Center Corp. |
Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
|
JP4793971B2
(ja)
|
1999-08-09 |
2011-10-12 |
メルク パテント ゲーエムベーハー |
複合サイトカイン−抗体複合体
|
|
EP1228214A2
(de)
|
1999-11-12 |
2002-08-07 |
MERCK PATENT GmbH |
Erythropoietinformen mit verbesserten eigenschaften
|
|
ATE336514T1
(de)
|
2000-02-11 |
2006-09-15 |
Merck Patent Gmbh |
Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
|
|
EP1935431A3
(de)
|
2000-05-15 |
2008-08-13 |
Health Research, Inc. |
Krebsbehandlungen unter Verwendung einer Kombination aus einem HER2-Antikörper und Interleukin-2
|
|
US6689353B1
(en)
*
|
2000-06-28 |
2004-02-10 |
Bayer Pharmaceuticals Corporation |
Stabilized interleukin 2
|
|
RU2272644C2
(ru)
|
2000-06-29 |
2006-03-27 |
Мерк Патент Гмбх |
Усиление иммунной реакции, медиатором которой является слитый протеин антитело-цитокин, при помощи комбинированного лечения агентами, увеличивающими поглощение иммуноцитокина
|
|
MY139948A
(en)
*
|
2000-09-28 |
2009-11-30 |
Bayer Corp |
Enhanced transfection system
|
|
US7723102B2
(en)
*
|
2000-09-28 |
2010-05-25 |
Bayer Corporation |
Enhanced transfection system
|
|
DK1366067T3
(da)
|
2001-03-07 |
2012-10-22 |
Merck Patent Gmbh |
Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
|
|
US6992174B2
(en)
|
2001-03-30 |
2006-01-31 |
Emd Lexigen Research Center Corp. |
Reducing the immunogenicity of fusion proteins
|
|
US6969517B2
(en)
|
2001-05-03 |
2005-11-29 |
Emd Lexigen Research Center Corp. |
Recombinant tumor specific antibody and use thereof
|
|
BR0214650A
(pt)
|
2001-12-04 |
2005-05-03 |
Merck Patent Gmbh |
Imunocitoquinas com seletividade modulada
|
|
ATE471946T1
(de)
|
2002-12-17 |
2010-07-15 |
Merck Patent Gmbh |
Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
|
|
US7569215B2
(en)
*
|
2003-07-18 |
2009-08-04 |
Massachusetts Institute Of Technology |
Mutant interleukin-2 (IL-2) polypeptides
|
|
DE602004031681D1
(de)
|
2003-07-21 |
2011-04-14 |
Transgene Sa |
Multifunktionelle Cytokine
|
|
DE602004031341D1
(de)
|
2003-07-21 |
2011-03-24 |
Transgene Sa |
Multifunktionelle cytokine
|
|
EP1682178B8
(de)
|
2003-11-04 |
2010-09-01 |
Novartis Vaccines and Diagnostics, Inc. |
Verfahren zur behandlung von krebs mit expression des cd40-antigens
|
|
JP5744369B2
(ja)
*
|
2004-02-27 |
2015-07-08 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
ＩＬ１５−Ｒα用ＩＬ−１５結合部位およびアゴニスト／アンタゴニスト活性を有する特異的ＩＬ−１５突然変異体
|
|
JP2007527242A
(ja)
*
|
2004-03-05 |
2007-09-27 |
カイロン コーポレーション |
治療剤の患者耐容性を予測するためのインビトロ試験システム
|
|
WO2009061853A2
(en)
*
|
2007-11-05 |
2009-05-14 |
Massachusetts Institute Of Technology |
Mutant interleukin-2 (il-2) polypeptides
|
|
CN101244261B
(zh)
*
|
2008-03-10 |
2010-09-15 |
山东大学 |
一种含未复性重组蛋白的生物制剂及其制备方法与应用
|
|
DE102008023820A1
(de)
*
|
2008-05-08 |
2009-11-12 |
Aicuris Gmbh & Co. Kg |
Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
|
|
MX2011007647A
(es)
|
2009-01-21 |
2011-09-01 |
Amgen Inc |
Composiciones y metodos para el tratamiento de enfermedades inflamatorias y autoinmunes.
|
|
CN102101885B
(zh)
*
|
2010-09-01 |
2013-06-05 |
南京发士达生物科技有限公司 |
低诱导抑制性t细胞的人白细胞介素ⅱ突变体及其用途
|
|
CU23923B1
(es)
*
|
2010-11-12 |
2013-07-31 |
Ct De Inmunología Molecular |
Polipéptidos derivados de la il-2 con actividad agonista
|
|
DK2637694T3
(da)
|
2010-11-12 |
2021-06-07 |
Nektar Therapeutics |
KONJUGATER AF EN Il-2-ENHED OG EN POLYMER
|
|
WO2012088446A1
(en)
*
|
2010-12-22 |
2012-06-28 |
Board Of Trustees Of The Leland Stanford Junior University |
Superagonists and antagonists of interleukin-2
|
|
MX340671B
(es)
|
2011-02-10 |
2016-07-20 |
Roche Glycart Ag |
Polipeptidos interleuquina- 2 mutantes.
|
|
WO2012119093A1
(en)
*
|
2011-03-03 |
2012-09-07 |
Board Of Trustees Of The Leland Stanford Junior University |
Superagonists and antagonists of interleukin-2
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
US20140044675A1
(en)
|
2012-08-10 |
2014-02-13 |
Roche Glycart Ag |
Interleukin-2 fusion proteins and uses thereof
|
|
CN105722860A
(zh)
|
2013-09-24 |
2016-06-29 |
梅迪塞纳医疗股份有限公司 |
白介素-2融合蛋白及其应用
|
|
WO2015118016A1
(en)
|
2014-02-06 |
2015-08-13 |
F. Hoffmann-La Roche Ag |
Interleukin-2 fusion proteins and uses thereof
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
CN106659757B
(zh)
|
2014-04-24 |
2022-01-28 |
利兰斯坦福初级大学董事会 |
白介素2的超级激动剂、部分激动剂和拮抗剂
|
|
MA40094B1
(fr)
|
2014-08-06 |
2022-05-31 |
Univ Miami |
Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
|
|
SG11201700629TA
(en)
|
2014-08-11 |
2017-02-27 |
Delinia Inc |
Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
|
CN108135978A
(zh)
|
2015-10-08 |
2018-06-08 |
尼克塔治疗公司 |
IL-2Rβ选择性激动剂和长效IL-15激动剂的组合
|
|
US20170204154A1
(en)
|
2016-01-20 |
2017-07-20 |
Delinia, Inc. |
Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
|
EP3280725B1
(de)
*
|
2016-05-04 |
2020-08-26 |
Amgen Inc. |
Interleukin-2-muteine zur expansion von t-regulatorischen zellen
|
|
EP3458485B1
(de)
|
2016-05-19 |
2021-12-29 |
The General Hospital Corporation |
An den rezeptor il-2rbeta gebundenes interleukin-2, eine plattform zur erhöhung der aktivität von natürlichen killer- und regulatorischen t-zellen
|
|
BR112018076281A2
(pt)
|
2016-06-20 |
2019-03-26 |
Kymab Limited |
imunocitocina, uso de uma imunocitocina, método, composição farmacêutica, método para tratar uma doença proliferativa em um animal, ácido nucleico, vetor, hospedeiro e anticorpo ou fragmento do mesmo
|
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
|
JP7206190B2
(ja)
*
|
2016-06-22 |
2023-01-17 |
ダヴィド・クラッツマン |
遺伝的に修飾されたｔリンパ球
|
|
US11779604B2
(en)
|
2016-11-03 |
2023-10-10 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses and methods
|
|
JP2019532996A
(ja)
|
2016-11-08 |
2019-11-14 |
デリニア，インコーポレーテッド |
自己免疫疾患を処置するためのｉｌ−２変異体
|
|
MX381276B
(es)
*
|
2016-12-13 |
2025-03-12 |
Delinia Inc |
Moduladores de linfocitos t reguladores multivalentes.
|
|
CN110520436A
(zh)
|
2017-03-15 |
2019-11-29 |
潘迪恩治疗公司 |
靶向免疫耐受性
|
|
EP3630163A4
(de)
|
2017-05-24 |
2021-06-09 |
Pandion Operations, Inc. |
Gezielte immuntoleranz
|
|
CN110662762A
(zh)
|
2017-05-24 |
2020-01-07 |
诺华股份有限公司 |
抗体细胞因子移植蛋白和用于治疗癌症的方法
|
|
US20200362058A1
(en)
*
|
2017-05-24 |
2020-11-19 |
Novartis Ag |
Antibody-cytokine engrafted proteins and methods of use
|
|
JOP20190271A1
(ar)
*
|
2017-05-24 |
2019-11-21 |
Novartis Ag |
بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
|
|
AU2018287317B2
(en)
|
2017-06-19 |
2024-06-20 |
Medicenna Therapeutics Inc. |
Uses and methods for IL-2 superagonists, agonists, and fusions thereof
|
|
BR112020002272A2
(pt)
*
|
2017-08-03 |
2020-07-28 |
Synthorx, Inc. |
conjugados de citocina para o tratamento de doenças autoimunes
|
|
KR102777151B1
(ko)
|
2017-11-21 |
2025-03-05 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
인터루킨-2의 부분 효능제
|
|
US10174091B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
|
USRE50550E1
(en)
|
2017-12-06 |
2025-08-26 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
US10946068B2
(en)
|
2017-12-06 |
2021-03-16 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
CN111655718B
(zh)
|
2017-12-19 |
2025-07-22 |
Xencor股份有限公司 |
经过工程化的il-2 fc融合蛋白
|
|
WO2019158764A1
(en)
|
2018-02-16 |
2019-08-22 |
Iltoo Pharma |
Use of interleukin 2 for treating sjögren's syndrome
|
|
SG11202007524QA
(en)
|
2018-03-28 |
2020-09-29 |
Ascendis Pharma Oncology Div A/S |
Il-2 conjugates
|
|
PE20210313A1
(es)
|
2018-03-28 |
2021-02-12 |
Bristol Myers Squibb Co |
Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso
|
|
WO2020007937A1
(en)
|
2018-07-03 |
2020-01-09 |
Iltoo Pharma |
Use of interleukin-2 for treating systemic sclerosis
|
|
AU2019311233B2
(en)
*
|
2018-07-24 |
2025-01-09 |
BioNTech SE |
IL2 agonists
|
|
WO2020035482A1
(en)
|
2018-08-13 |
2020-02-20 |
Iltoo Pharma |
Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
|
|
WO2020060122A1
(ko)
*
|
2018-09-17 |
2020-03-26 |
(주)지아이이노베이션 |
Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 이의 용도
|
|
JP7512210B2
(ja)
|
2018-09-21 |
2024-07-08 |
イノベント バイオロジックス （スウツォウ） カンパニー，リミテッド |
新規インターロイキン２およびその使用
|
|
AU2019409196A1
(en)
|
2018-12-21 |
2021-06-17 |
Jiangsu Hengrui Medicine Co., Ltd. |
Human interleukin-2 variant or derivative thereof
|
|
MX2021014178A
(es)
|
2019-05-20 |
2022-01-04 |
Pandion Operations Inc |
Inmunotolerancia dirigida a la molecula de adhesion celular de adresina vascular de mucosas (madcam).
|
|
TW202115105A
(zh)
*
|
2019-06-24 |
2021-04-16 |
德商拜恩迪克Ｒｎａ製藥有限公司 |
Ｉｌ２激動劑
|
|
EP4004025A1
(de)
|
2019-07-26 |
2022-06-01 |
Visterra, Inc. |
Interleukin-2-wirkstoffe und verwendungen davon
|
|
JP2022544236A
(ja)
*
|
2019-08-13 |
2022-10-17 |
アムジエン・インコーポレーテツド |
制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質
|
|
EP4073094A1
(de)
|
2019-12-12 |
2022-10-19 |
Iltoo Pharma |
Chimäre interleukin-2-konstrukte
|
|
JOP20220151A1
(ar)
|
2019-12-17 |
2023-01-30 |
Amgen Inc |
ناهض مستقبل إنترلوكين -2 / tnf المزدوج للاستخدام في العلاج
|
|
EP4087865A2
(de)
|
2020-01-10 |
2022-11-16 |
Bright Peak Therapeutics AG |
Modifizierte il-2-polypeptide und verwendungen davon
|
|
MX2022008771A
(es)
|
2020-01-14 |
2022-10-07 |
Synthekine Inc |
Metodos y composiciones de muteinas de il2 sesgadas.
|
|
US20230210951A1
(en)
*
|
2020-01-14 |
2023-07-06 |
Synthekine, Inc. |
Il2 muteins
|
|
EP4107187A4
(de)
|
2020-02-21 |
2024-07-03 |
Pandion Operations, Inc. |
Gewebegezielte immuntoleranz mit einem cd39-effektor
|
|
CN115698052A
(zh)
|
2020-03-19 |
2023-02-03 |
信达生物制药(苏州)有限公司 |
白介素2突变体及其用途
|
|
CN118271419A
(zh)
|
2020-03-31 |
2024-07-02 |
韩美药品株式会社 |
新型免疫刺激il-2类似物
|
|
EP4161956A1
(de)
|
2020-06-03 |
2023-04-12 |
Ascendis Pharma Oncology Division A/S |
Il-2-sequenzen und verwendungen davon
|
|
US20240325495A1
(en)
|
2020-10-29 |
2024-10-03 |
Bristol-Myers Squibb Company |
Fusion proteins for the treatment of disease
|
|
CN114507643A
(zh)
*
|
2020-10-29 |
2022-05-17 |
未来智人再生医学研究院(广州)有限公司 |
一种表达il-2的多能干细胞衍生物及应用
|
|
TW202237171A
(zh)
|
2020-12-04 |
2022-10-01 |
美商威特拉公司 |
使用介白素-2藥劑之方法
|
|
CN113308477A
(zh)
*
|
2021-04-08 |
2021-08-27 |
华南农业大学 |
一种鸭il-2基因真核表达重组质粒及其制备方法
|
|
CA3233075A1
(en)
|
2021-09-22 |
2023-03-30 |
Fortvita Biologics (Singapore) Pte. Ltd. |
Interleukin-2 mutant and fusion protein thereof
|
|
EP4412631A1
(de)
|
2021-10-06 |
2024-08-14 |
Iltoo Pharma |
Chimäre interleukin-2-konstrukte mit targeting von spezifisch für entzündete gewebe
|
|
CN114875069B
(zh)
*
|
2022-04-22 |
2023-09-15 |
四川大学 |
基因工程修饰的il2细胞因子的重组载体、宿主细胞及其用途
|
|
TW202413442A
(zh)
|
2022-06-16 |
2024-04-01 |
美商希佛隆有限責任公司 |
抗pd-1抗體減弱之il-2免疫結合物及其用途
|
|
KR20250113390A
(ko)
|
2022-09-12 |
2025-07-25 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
자폐 스펙트럼 장애 치료에 사용되는 인터루킨-2
|
|
FR3140287B1
(fr)
|
2022-10-03 |
2025-11-21 |
Arkema France |
Procede de granulation de composes azoiques et granules obtenus
|
|
CN118056840A
(zh)
|
2022-11-18 |
2024-05-21 |
南京诺艾新生物技术有限公司 |
受体亲和力偏好性的定点偶联聚乙二醇化白介素-2突变体及其用途
|